225 related articles for article (PubMed ID: 26141060)
1. PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma.
Wang Y; Wang H; Zhao Q; Xia Y; Hu X; Guo J
Med Oncol; 2015 Aug; 32(8):212. PubMed ID: 26141060
[TBL] [Abstract][Full Text] [Related]
2. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
[TBL] [Abstract][Full Text] [Related]
3. Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling.
Yang Z; Xie H; He D; Li L
Oncotarget; 2016 Jul; 7(28):44478-44491. PubMed ID: 27283897
[TBL] [Abstract][Full Text] [Related]
4. LINC00961 restrains cancer progression via modulating epithelial-mesenchymal transition in renal cell carcinoma.
Chen D; Zhu M; Su H; Chen J; Xu X; Cao C
J Cell Physiol; 2019 May; 234(5):7257-7265. PubMed ID: 30367453
[TBL] [Abstract][Full Text] [Related]
5. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
[TBL] [Abstract][Full Text] [Related]
6. High expression of the long non-coding RNA HEIRCC promotes Renal Cell Carcinoma metastasis by inducing epithelial-mesenchymal transition.
Xiong J; Liu Y; Luo S; Jiang L; Zeng Y; Chen Z; Shi X; Lv B; Tang W
Oncotarget; 2017 Jan; 8(4):6555-6563. PubMed ID: 28030807
[TBL] [Abstract][Full Text] [Related]
7. Cyclic AMP responsive element-binding protein induces metastatic renal cell carcinoma by mediating the expression of matrix metallopeptidase-2/9 and proteins associated with epithelial-mesenchymal transition.
Wang X; Cui H; Lou Z; Huang S; Ren Y; Wang P; Weng G
Mol Med Rep; 2017 Jun; 15(6):4191-4198. PubMed ID: 28487942
[TBL] [Abstract][Full Text] [Related]
8. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
Alsuliman A; Colak D; Al-Harazi O; Fitwi H; Tulbah A; Al-Tweigeri T; Al-Alwan M; Ghebeh H
Mol Cancer; 2015 Aug; 14():149. PubMed ID: 26245467
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma.
Yoshino H; Enokida H; Itesako T; Tatarano S; Kinoshita T; Fuse M; Kojima S; Nakagawa M; Seki N
J Hum Genet; 2013 Aug; 58(8):508-16. PubMed ID: 23635949
[TBL] [Abstract][Full Text] [Related]
10. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
11. SPOP promotes tumor progression via activation of β-catenin/TCF4 complex in clear cell renal cell carcinoma.
Zhao W; Zhou J; Deng Z; Gao Y; Cheng Y
Int J Oncol; 2016 Sep; 49(3):1001-8. PubMed ID: 27572476
[TBL] [Abstract][Full Text] [Related]
12. TNF-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3β-dependent mechanism.
Ho MY; Tang SJ; Chuang MJ; Cha TL; Li JY; Sun GH; Sun KH
Mol Cancer Res; 2012 Aug; 10(8):1109-19. PubMed ID: 22707636
[TBL] [Abstract][Full Text] [Related]
13. miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.
Liu Y; Zhang M; Qian J; Bao M; Meng X; Zhang S; Zhang L; Zhao R; Li S; Cao Q; Li P; Ju X; Lu Q; Li J; Shao P; Qin C; Yin C
DNA Cell Biol; 2015 Jun; 34(6):429-36. PubMed ID: 25811077
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
15. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of SOX4 promotes cell migration and invasion of renal cell carcinoma by inducing epithelial-mesenchymal transition.
Ruan H; Yang H; Wei H; Xiao W; Lou N; Qiu B; Xu G; Song Z; Xiao H; Liu L; Zhou Y; Hu W; Chen K; Chen X; Zhang X
Int J Oncol; 2017 Jul; 51(1):336-346. PubMed ID: 28534986
[TBL] [Abstract][Full Text] [Related]
17. KDM6B induces epithelial-mesenchymal transition and enhances clear cell renal cell carcinoma metastasis through the activation of SLUG.
Li Q; Hou L; Ding G; Li Y; Wang J; Qian B; Sun J; Wang Q
Int J Clin Exp Pathol; 2015; 8(6):6334-44. PubMed ID: 26261509
[TBL] [Abstract][Full Text] [Related]
18. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
Abbas M; Steffens S; Bellut M; Becker JU; Großhennig A; Eggers H; Wegener G; Kuczyk MA; Kreipe HH; Grünwald V; Schrader AJ; Ivanyi P
Med Oncol; 2016 Jun; 33(6):59. PubMed ID: 27165272
[TBL] [Abstract][Full Text] [Related]
19. High expression of fructose-bisphosphate aldolase A induces progression of renal cell carcinoma.
Huang Z; Hua Y; Tian Y; Qin C; Qian J; Bao M; Liu Y; Wang S; Cao Q; Ju X; Wang Z; Gu M
Oncol Rep; 2018 Jun; 39(6):2996-3006. PubMed ID: 29693182
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of ETS2 inhibits the invasion and metastasis of renal cell carcinoma cells by inducing EMT via the PI3K/Akt signaling pathway.
Zhang GW; Tian X; Li Y; Wang ZQ; Li XD; Zhu CY
Biomed Pharmacother; 2018 Aug; 104():119-126. PubMed ID: 29772431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
